A Retrospective, Monocentric Study Comparing Co and Secondary Infections in Critically Ill COVID-19 and Influenza Patients.
COVID-19
Influenza
aspergillosis
co-infection
secondary infections
Journal
Antibiotics (Basel, Switzerland)
ISSN: 2079-6382
Titre abrégé: Antibiotics (Basel)
Pays: Switzerland
ID NLM: 101637404
Informations de publication
Date de publication:
24 May 2022
24 May 2022
Historique:
received:
22
04
2022
revised:
17
05
2022
accepted:
20
05
2022
entrez:
24
6
2022
pubmed:
25
6
2022
medline:
25
6
2022
Statut:
epublish
Résumé
Few data are available on infectious complications in critically ill patients with different viral infections. We performed a retrospective monocentric study including all of the patients admitted to the intensive care unit (ICU) with confirmed COVID-19 (as of 13 March 2020) or Influenza A and/or B infections (as of 1 January 2015) until 20 April 2020. Coinfection and secondary infections (occurring within and after 48 h from admission, respectively) were recorded. Fifty-seven COVID-19 and 55 Influenza patients were included. Co-infections were documented in 13/57 (23%) COVID-19 patients vs. 40/55 (73%) Influenza patients (p < 0.001), most of them being respiratory (9/13, 69% vs. 35/40, 88%; p = 0.13) and of bacterial origin (12/13, 92% vs. 29/40, 73%; p = 0.25). Invasive aspergillosis infections were observed only in Influenza patients (8/55, 15%). The COVID-19 and Influenza patients presented 1 (0−4) vs. 0 (0−4) secondary infections (p = 0.022), with comparable sites being affected (lungs: 35/61, 57% vs. 13/31, 42%; p = 0.16) and causative pathogens occurring (Gram-negative bacteria: 51/61, 84% vs. 23/31, 74%; p > 0.99). The COVID-19 patients had longer ICU lengths of stay (15 (−65) vs. 5 (1−89) days; p = 0.001), yet the two groups had comparable mortality rates (20/57, 35% vs. 23/55, 41%; p = 0.46). We report fewer co-infections but more secondary infections in the ICU COVID-19 patients compared to the Influenza patients. Most of the infectious complications were respiratory and of bacterial origin.
Identifiants
pubmed: 35740112
pii: antibiotics11060704
doi: 10.3390/antibiotics11060704
pmc: PMC9219538
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
Intensive Care Med. 2019 Feb;45(2):172-189
pubmed: 30659311
Ann Intensive Care. 2020 Sep 7;10(1):119
pubmed: 32894364
Clin Infect Dis. 2021 Dec 6;73(11):e3606-e3614
pubmed: 32719848
Sci Rep. 2021 Jun 16;11(1):12703
pubmed: 34135459
Multidiscip Respir Med. 2021 Oct 28;16(1):793
pubmed: 34760275
J Infect. 2020 Aug;81(2):266-275
pubmed: 32473235
Nat Rev Microbiol. 2014 Apr;12(4):252-62
pubmed: 24590244
J Infect. 2021 Feb;82(2):e20-e21
pubmed: 32956729
Intensive Care Med. 2020 Aug;46(8):1524-1535
pubmed: 32572532
Pharmacotherapy. 2021 Nov;41(11):884-906
pubmed: 34558742
Crit Care. 2020 Dec 18;24(1):699
pubmed: 33339526
JAMA. 2001 Oct 10;286(14):1754-8
pubmed: 11594901
Influenza Other Respir Viruses. 2016 Sep;10(5):394-403
pubmed: 27232677
Intensive Care Med. 2017 Jan;43(1):48-58
pubmed: 27709265
Eur J Clin Microbiol Infect Dis. 2021 Mar;40(3):495-502
pubmed: 33389263
Lancet Respir Med. 2021 Mar;9(3):251-259
pubmed: 33341155
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
Clin Infect Dis. 2016 Aug 15;63(4):e1-e60
pubmed: 27365388
Clin Microbiol Infect. 2020 Dec;26(12):1622-1629
pubmed: 32711058
Intensive Care Med. 2005 Oct;31(10):1345-55
pubmed: 16132892
Eur J Clin Microbiol Infect Dis. 2021 May;40(5):987-995
pubmed: 33274416
Infection. 2021 Jun;49(3):559-562
pubmed: 33393065
Ann Intern Med. 2009 May 5;150(9):604-12
pubmed: 19414839
J Clin Virol. 2015 Nov;72:36-41
pubmed: 26364158
Lancet Infect Dis. 2020 Jun;20(6):697-706
pubmed: 32224310
Intensive Care Med. 2020 Sep;46(9):1787-1789
pubmed: 32661615
J Hosp Infect. 2021 Jan;107:95-97
pubmed: 33217490